Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - alirocumab 150 mg/ml;   - solution for injection - 150 mg/ml - active: alirocumab 150 mg/ml   excipient: histidine polysorbate 20 sucrose water for injection - primary hypercholesterolaemia praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - alirocumab 75 mg/ml;   - solution for injection - 75 mg/ml - active: alirocumab 75 mg/ml   excipient: histidine polysorbate 20 sucrose water for injection - primary hypercholesterolaemia praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Europeiska unionen - engelska - EMA (European Medicines Agency)

sanofi winthrop industrie - alirocumab - dyslipidemias - lipid modifying agents - primary hypercholesterolaemia and mixed dyslipidaemiapraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.established atherosclerotic cardiovascular disease praluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.for study results with respect to effects on ldl-c, cardiovascular events and populations studied see section 5.1.

Kanada - engelska - Health Canada

sanofi-aventis canada inc - alirocumab - solution - 75mg - alirocumab 75mg - proprotein convertase subtilisin kexin type 9 (pcsk9) inhibitors

Kanada - engelska - Health Canada

sanofi-aventis canada inc - alirocumab - solution - 150mg - alirocumab 150mg - proprotein convertase subtilisin kexin type 9 (pcsk9) inhibitors

Kanada - engelska - Health Canada

sanofi-aventis canada inc - alirocumab - solution - 75mg - alirocumab 75mg - proprotein convertase subtilisin kexin type 9 (pcsk9) inhibitors

Kanada - engelska - Health Canada

sanofi-aventis canada inc - alirocumab - solution - 150mg - alirocumab 150mg - proprotein convertase subtilisin kexin type 9 (pcsk9) inhibitors

Singapore - engelska - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - alirocumab - injection, solution - alirocumab 150mg

Singapore - engelska - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - alirocumab - injection, solution - alirocumab 75mg

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - alirocumab - solution for injection - 75mg/1ml